IQVIA Holdings Inc. (IQV) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services...
IQVIA Holdings Inc.'s revenue increased 5.9% year over year, from $15.40B to $16.31B.
Net income decreased 0.9% over the same period, from $1.37B to $1.36B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 137% in total.
Total debt increased by 8.1% to $13.88B.
The debt-to-equity ratio stands at 2.14, indicating a high leverage profile.
Operating cash flow declined 2.3% to $2.65B.
IQVIA Holdings Inc. maintains a moderate net profit margin of 8.3%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $11.12B+50.6% | $889.0M | N/A | $1.48B | $1.40B | $25.98B | $12.32B | $5.80B |
| Q1 FY2024 | $3.74B-66.4% | $288.0M | N/A | $506.0M | $522.0M | $26.57B | $12.82B | $6.34B |
| Q2 FY2024 | $7.55B+102.1% | $651.0M | N/A | $1.03B | $1.11B | $26.40B | $12.09B | $6.71B |
| Q3 FY2024 | $11.45B+51.6% | $936.0M | N/A | $1.58B | $1.83B | $27.18B | $12.29B | $6.97B |
| Q1 FY2025 | $3.83B-66.6% | $249.0M | N/A | $496.0M | $568.0M | $27.32B | $13.11B | $5.98B |
| Q2 FY2025 | $7.85B+104.9% | $515.0M | N/A | $1.00B | $1.01B | $28.63B | $14.18B | $5.78B |
| Q3 FY2025 | $11.95B+52.3% | $846.0M | N/A | $1.55B | $1.92B | $28.73B | $12.79B | $6.16B |
| Q1 FY2026 | $4.15B-65.3% | $274.0M | N/A | $514.0M | $618.0M | $29.68B | $13.99B | $6.22B |
Balance Sheet Summary (Latest Period)
Total Assets
$29.94B
Total Liabilities
$23.31B
Total Equity
$6.50B
Cash & Equivalents
$2.14B
Total Debt
$13.88B
Current Assets
$6.25B
Current Liabilities
$8.34B
Retained Earnings
$7.42B